Checkpoint' Cancer Therapy Shows Almost 55% Response Rate In Skin Cancer Patients
Checkpoint Therapeutics Inc (NASDAQ: CKPT) announced positive interim efficacy results from its registration-enabling trial of cosibelimab, in patients with locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation.
The design of the interim analysis incorporated recent FDA feedback and is intended to support the approval of cosibelimab in this indication potentially.
As of the March 2022 data cutoff, the objective response rate (ORR) in 31 patients was 54.8%, substantially exceeding a clinically meaningful lower bound of 25%.
Checkpoint intends to continue discussions with the FDA on potentially adding locally advanced cSCC as a second indication in the planned marketing application submission later this year.
Checkpoint previously reported positive top-line data from a cohort of 78 patients with metastatic cSCC in its pivotal trial of cosibelimab.
Related: Checkpoint Therapeutics' Cosibelimab Posts 47.4% ORR In Skin Cancer Patients.
Checkpoint licensed Cosibelimab in 2015 from the Dana-Farber Cancer Institute.
Price Action: CKPT shares are down 1.85% at $1.06 during the premarket session on the last check Thursday.
See more from Benzinga
Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap Biopharma
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.